Author Topic: (MSAA) Ocrelizumab shows positive results in treating PPMS  (Read 135 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8564
  • MS diagnosed 1980
  • Location: Pacific Northwest
Roche to pursue Ocrelizumab drug market authorization
« on: November 17, 2015, 08:51:10 pm »
From Multiple Sclerosis News Today, November 16, 2015:

Roche to Pursue MS Ocrelizumab Drug Market Authorization

Data on PPMS and RMS groundbreaking therapy ocrelizumab will be submitted to global regulatory authorities
Patricia Silva, PhD

Roche recently provided an update on their late-stage pipeline products across several therap-eutic areas, including ocrelizumab for the treatment of multiple sclerosis. The data was disclosed on Nov. 5 at the Roche Pharma Day 2015 event in London, U.K.

Ocrelizumab was previously revealed to be the first investigational medicine to have a positive impact in two forms of multiple sclerosis, primary progressive multiple sclerosis (PPMS) and relapsing multiple sclerosis (RMS). Ocrelizumab is a recombinant humanized monoclonal antibody against immune B cells that express CD20 proteins at their surface. These cells are thought to be a key contributor to the myelin and neuron damage that leads to motor function impairment, irreversible neurological disability, and paralysis in multiple sclerosis patients. Roche is planning to submit data on ocrelizumab to global regulatory authorities in early 2016 to obtain marketing authorization for the drug as a potential new therapy for RMS and a first approved treatment for PPMS.

Apart from the update on the company’s most advanced investigational therapeutics presented at the event, executives also briefed investors and analysts on Roche’s strategy, R&D productivity, management and new market opportunities. Roche’s strategy is to continue to focus on innovation and treatment advancement across a range of high medical need areas. The company plans to further explore the wealth of molecular data becoming available and use that information in drug discovery and development.

“Thanks to our diversified late-stage portfolio we are well positioned to maintain our leadership in oncology, expand further in the immunology and ophthalmology segments, and potentially offer new treatments to help improve the lives of people with multiple sclerosis and haemophilia,” said Daniel O’Day, COO of Roche’s Pharmaceuticals Division in a news release. “And we are looking to harness the vast increase in molecular information as the next important step in our efforts to develop even better, more personalized treatment solutions.”
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.